Application of deubiquitinating enzyme inhibitor in preparation of medicine for resisting rabies virus
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ACAD OF MILITARY SCI PLA CHINA ACAD OF MILITARY MEDICAL SCI INST OF MILITARY VETERINARY MEDICINE
- Publication Date
- 2021-06-11
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention relates to the technical field of medicine, in particular to the use of deubiquitinating enzyme inhibitors in the preparation of anti-rabies virus medicines. Background technique
[0002] Rabies is a highly lethal zoonotic disease caused by rabies virus, which is characterized by invading the central nervous system and causing encephalitis in humans and other mammals. According to statistics, more than 60,000 people die from rabies every year in the world, and more than 15 million people receive post-exposure prophylaxis. Until now, rabies remains an incurable disease, and the only way to prevent it is through pre-exposure or post-exposure vaccination. Once clinical symptoms appear, the case fatality rate is as high as 100%. Therefore, the treatment of rabies is of great significance, and the research on finding anti-rabies virus drugs is imminent.
[0003] PR-619 is a cell-permeable, broad, reversible deubiquitinating enzyme inhibitor...